Drug intelligence / Profile preview

respiratory syncytial virus mRNA vaccine

Development stage: Unknown
Lead developer: AlphaNa Bioscience
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The respiratory syncytial virus (RSV) mRNA vaccine is a prophylactic biologic candidate developed by Hefei Afana Biotechnology Co., Ltd. designed to prevent infections caused by RSV, particularly in older adults. Utilizing mRNA technology, the vaccine delivers genetic instructions (typically encapsulated in lipid nanoparticles) to host cells to express a stabilized version of the RSV fusion (F) protein. This expression triggers the immune system to produce neutralizing antibodies and activate T-cell responses against the virus. The vaccine is currently being evaluated in Phase II clinical trials to assess its safety, immunogenicity, and the persistence of the immune response in individuals aged 50 and older.

Other names: RSV mRNA vaccine呼吸道合胞病毒mRNA疫苗

Targets

PRR (Pattern recognition receptors)RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on respiratory syncytial virus mRNA vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on respiratory syncytial virus mRNA vaccine.

Explore the full profile